Carbamazepine, 98%

Name: Carbamazepine, 98%
SKU: 344360250

Carbamazepine (Carbamazepen), CAS # 298-46-4, is an aromatic ring of the dibenzoazepine class that acts as a sodium channel blocker. | CAS: 298-46-4 | C15H12N2O | 236.27 g/mol

テクニカルサポートオーダーサポート

表示を変更

数量:

1 g

5 g

25 g

パッケージ:

Glass bottle

Chem dex^TM Webアプリをお試しください

製品番号（カタログ番号） 344360250

価格（JPY）

見積もりを依頼する

数量:

25 g

パッケージ:

Glass bottle

一括またはカスタム形式をリクエストする

化学物質識別子

CAS298-46-4

IUPAC Name2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide

Molecular FormulaC15H12N2O

InChI KeyFFGPTBGBLSHEPO-UHFFFAOYSA-N

SMILESNC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12

さらに表示

仕様

スペックシート

Infrared spectrumConforms

Appearance (Color)White to off-white

HPLC>=97.5 %

Appearance (Form)Powder or crystals

Melting point189°C to 193°C

This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

General Description

Carbamazepine is an aromatic ring of the dibenzoazepine class that acts as a sodium channel blocker
It is a tricyclic antidepressant-like drug that reduces post-tetanic potentiation

Applications

Carbamazepine can be used as a sodium channel blocker and as a glutamate-transporter agonist to reduce neural activity and produce inhibitory effects in the brain
Carbamazepine is useful in the research of pain, epilepsy, and manic depression

RUO – Research Use Only

General References:

Ben-Menachem, E.; Grebe, H.P.; Terada, K.; Jensen, L.; Li, T.; De Backer, M.; Steiniger-Brach, B.; Gasalla, T.; Brock, M.; Biton, V. Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. Epilepsia. 2019, 60(12), 2437-2447. Erratum in: Epilepsia. 2021, 62(4), 1039.
Schmitz, B.; Dimova, S.; Zhang, Y.; Chellun, D.; De Backer, M.; Gasalla, T. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. Epilepsy Res. 2020, 159, 106220.